| Budget Amount *help |
¥17,030,000 (Direct Cost: ¥13,100,000、Indirect Cost: ¥3,930,000)
Fiscal Year 2020: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
Fiscal Year 2019: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
Fiscal Year 2018: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
|
|---|
| Outline of Final Research Achievements |
Molecular targeted therapies, such as monoclonal antibodies, were widely used for various cancers recently, leading to improve patients’ outcomes. Photoimmunotherapy (PIT) is a new class of molecular targeted cancer theranostics, which employs monoclonal antibody conjugated to a photosensitizer, IR700, that is activated by focal near-infrared (NIR) light irradiation leading to necrotic cell death. In this study, we developed a new type of PIT agents targeting VEGFR-2 expressed on vascular endothelium in a tumor stroma and Trop2 expressed on various types of cancer cell. We also developed photoactivatable functionalized liposome that can be used for PIT. Further study is needed for clinical translation,
|
